HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanotech products proliferating

This article was originally published in The Rose Sheet

Executive Summary

The number of consumer goods with claims to nanotechnology has more than doubled from 212 to 475 in the 14 months since the Wilson Center's Project on Emerging Nanotechnologies (PEN) launched its online inventory of manufacturer-identified nanotech goods in March 2006, PEN announces June 4. Nanoscale silver - found in 20% of the goods listed - is the most common nanomaterial used; carbon - including carbon nanotubes and fullerenes - is the second-most-used material, PEN says. The U.S. leads nanotech use internationally, manufacturing 52% of the products listed, though East Asia now boasts 123 products, a 58% increase over last year, PEN states. "The use of nanotechnology in consumer products and industrial applications is growing rapidly, with the products listed in the inventory showing just the tip of the iceberg," PEN Science Advisor Andrew Maynard remarks...

You may also be interested in...



Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel